Dyax Corp. (DYAX) Reports Statistically Significant Results in Trials to Fight Hereditary Angioedema
Read the full article: http://blog.qualitystocks.net/?p=11807
Dyax Corp. (Nasdaq: DYAX) is a clinical-stage drug company focused on the discovery, development and commercialization of biotherapeutics for oncology and inflammatory conditions. The company today announced positive topline results from its second phase-3, placebo-controlled trial, EDEMA4, for its lead product candidate DX-88 (ecallantide) for hereditary angioedema (HAE), or the rapid swelling of the skin.
- Login or register to post comments
- Email this page
Related Articles
- Dyax Corp. (DYAX) Announces Completion of Biologics License Application with FDA; Moves Forward with Treatment for Life-Threaten
- GenVec, Inc.’s (GNVC) TNFerade™ Gets FDA Fast Track Designation for Pancreatic Cancer Treatment
- CardioVascular Biotherapeutics Inc. (CVBT.OB) Finds Significant Private Funding for Topical Diabetic Wound Care Rollout
- China Medicine Corporation (CHME.OB) Reports Surge in Second Quarter Profit
- China Pharma Holdings Inc. (CPHI.OB) Posts Positive Q3 Results Across the Board